{"id":47700,"date":"2026-07-30T02:45:00","date_gmt":"2026-07-30T00:45:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=7d510397ce4859c773085a7cdc670bd2"},"modified":"2026-07-30T02:45:00","modified_gmt":"2026-07-30T00:45:00","slug":"sail-biomedicines-announces-strategic-collaboration-to-develop-new-class-of-medicines-for-in-vivo-car-t","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=47700","title":{"rendered":"Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T"},"content":{"rendered":"<ul class=\"bwlistdisc\">\n<li>\nCombines Sail\u2019s patented eRNA\u2122 and targeted nanoparticle modality with Johnson &amp; Johnson\u2019s world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-mediated diseases<\/li>\n<li>\nSail to receive initial payments of $785 million from Johnson &amp; Johnson<sup>1<\/sup>, including a $465 million equity investment<sup>2<\/sup> and additional milestone payments of $140 million subject to achievement of certain development milestones<\/li>\n<li>\nJohnson &amp; Johnson<sup>3<\/sup> to obtain an exclusive option to acquire Sail for an additional $2.58 billion<\/li>\n<\/ul><p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--<a href=\"https:\/\/twitter.com\/hashtag\/InVivoCART?src=hash\" >#InVivoCART<\/a>--Sail Biomedicines, a Flagship Pioneering company creating a new class of RNA medicines, today announced a strategic collaboration with Johnson &amp; Johnson to advance innovative In Vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies that have the potential to improve patient outcomes for immune-mediated diseases. The collaboration will combine Sail\u2019s pioneering AI-driven product design using its proprietary eRNA\u2122 and targeted nanoparticle platform with Johnson &amp; Johnson\u2019s world-class capabilities in drug development, manufacturing, and commercialization. The companies will advance Sail\u2019s vanguard In Vivo CAR-T program in autoimmune diseases while pursuing additional programs that leverage Sail\u2019s industry leading product engine to build a portfolio of In Vivo CAR-T medicines designed to drive durable disease remission by resetting the immune system.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260728202837\/en\/2085155\/5\/Sail_Biomedicines_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260728202837\/en\/2085155\/22\/Sail_Biomedicines_Logo.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260728202837\/en\/2085155\/5\/Sail_Biomedicines_Logo.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260728202837\/en\/2085155\/21\/Sail_Biomedicines_Logo.jpg\" \/><\/a><p>\nSail has built an integrated product engine with the potential to turn the promise of In Vivo CAR-T into a scalable class of medicines based on pioneering research done in Flagship Labs. By designing eRNA\u2122 constructs, targeted nanoparticles, and manufacturing as one coordinated system, Sail can direct what therapeutic instructions are delivered, which cells receive them, and how long they are expressed.<\/p><p>\n\u201cWe believe In Vivo CAR-T therapies have the potential to create a disruptive paradigm shift \u2014 from chronic treatments to potentially curative medicines for patients with immune-mediated diseases,\u201d said John D. Mendlein, Ph.D., Executive Chairman of Sail Biomedicines and Executive Partner at Flagship Pioneering. \u201cOur new class of medicines offers an innovative therapeutic horizon for patients and providers \u2014 powerful, accessible, and scalable products. We are thrilled to work with Johnson &amp; Johnson\u2019s scientists and leadership on our shared vision of bringing curative impact to millions of people with immune-mediated diseases.\u201d<\/p><p>\nUnder the terms of the agreements, Johnson &amp; Johnson would make total initial payments of $785 million, including a $465 million equity investment, and additional payments of $140 million dependent on the achievement of certain development milestones. Subject to Johnson &amp; Johnson\u2019s decision to exercise the option, Johnson &amp; Johnson would make an additional payment of $2.58 billion.<\/p><p>\n<b>About Sail Biomedicines<\/b><\/p><p>\nSail Biomedicines is creating a new class of RNA medicines designed to instruct therapeutic activity directly inside a patient\u2019s body and within selected cells. Sail\u2019s platform integrates Endless RNA\u2122 (eRNA\u2122), targeted nanoparticle delivery, and AI-enabled design to develop medicines with optimized therapeutic performance. The company is focused on applying its platform to In Vivo CAR-T medicines for immune-mediated diseases, with the goal of bringing the curative potential of CAR-T cell therapy to substantially more patients. Sail was founded by Flagship Pioneering and is headquartered in Cambridge, Massachusetts. For more, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sail.bio%2F&amp;esheet=54578854&amp;newsitemid=20260728202837&amp;lan=en-US&amp;anchor=www.sail.bio&amp;index=1&amp;md5=71cbec258523e65a8bdd02327eb81865\" rel=\"nofollow\" shape=\"rect\">www.sail.bio<\/a> and follow us on X (<a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fx.com%2FSailBiomeds&amp;esheet=54578854&amp;newsitemid=20260728202837&amp;lan=en-US&amp;anchor=%40SailBiomeds&amp;index=2&amp;md5=67b2a4cc3985c96382d7406cc6351c62\" rel=\"nofollow\" shape=\"rect\">@SailBiomeds<\/a>) and <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsail-biomedicines&amp;esheet=54578854&amp;newsitemid=20260728202837&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=9d102f312545aba92aa5ad53f5f262dd\" rel=\"nofollow\" shape=\"rect\">LinkedIn<\/a>.<\/p><p>\n<sup>1<\/sup> Collaboration agreement between Sail and Janssen Biotech, Inc., a Johnson &amp; Johnson company.\n<br\/><sup>2<\/sup> Equity investment made by Johnson &amp; Johnson Innovation \u2013 JJDC Inc., Johnson &amp; Johnson\u2019s corporate venture capital arm.\n<br\/><sup>3<\/sup> Payments to be allocated amongst Sail and Sail shareholders based on the terms of the agreements.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<a  href=\"mailto:press@flagshippioneering.com\" rel=\"nofollow\" shape=\"rect\">press@flagshippioneering.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Combines Sail\u2019s patented eRNA\u2122 and targeted nanoparticle modality with Johnson &amp; Johnson\u2019s world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-m&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-47700","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=47700"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47700\/revisions"}],"predecessor-version":[{"id":47702,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/47700\/revisions\/47702"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=47700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=47700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=47700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}